Department of Physiology, Faculty of Medicine, University of Valencia, Research Foundation of the University Clinic Hospital of Valencia/INCLIVA, Valencia, Spain.
J Strength Cond Res. 2012 Mar;26(3):608-10. doi: 10.1519/JSC.0b013e31824301b6.
The World Antidoping Agency (WADA) has introduced some changes in the 2012 prohibited list. Among the leading innovations to the rules are that both 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (peroxisome proliferator-activated receptor-δ [PPAR-δ]-5' adenosine monophosphate-activated protein kinase [AMPK] agonist) and GW1516 (PPAR-δ-agonist) are no longer categorized as gene doping substances in the new 2012 prohibited list but as metabolic modulators in the class "Hormone and metabolic modulators." This may also be valid for the angotensin II receptor blocker telmisartan. It has recently been shown that telmisartan might induce similar biochemical, biological, and metabolic changes (e.g., mitochondrial biogenesis and changes in skeletal muscle fiber type) as those reported for the former call of substances. We suspect that metabolic modulators abuse such as telmisartan might become a tangible threat in sports and should be thereby targeted as an important antidoping issue. The 2012 WADA prohibited list does not provide telmisartan for a potential doping drug, but arguments supporting the consideration to include them among "metabolic modulators" are at hand.
世界反兴奋剂机构（WADA）在 2012 年禁用清单中引入了一些变化。规则的主要创新之一是，5-氨基咪唑-4-甲酰胺-1-β-D-核糖呋喃糖苷（过氧化物酶体增殖物激活受体-δ[PPAR-δ]-5'腺苷单磷酸激活蛋白激酶[AMPK]激动剂）和 GW1516（PPAR-δ-激动剂）不再被归类为新的 2012 年禁用清单中的基因兴奋剂物质，而是归类为“激素和代谢调节剂”类别中的代谢调节剂。血管紧张素 II 受体阻滞剂替米沙坦也可能如此。最近有研究表明，替米沙坦可能会引起与以前报告的物质类似的生化、生物学和代谢变化（例如，线粒体生物发生和骨骼肌纤维类型的变化）。我们怀疑替米沙坦等代谢调节剂的滥用可能会对运动构成切实威胁，因此应将其作为一个重要的反兴奋剂问题加以解决。2012 年 WADA 禁用清单没有将替米沙坦列为潜在的兴奋剂药物，但支持将其列入“代谢调节剂”的论点已经存在。
